Keywords
How to Cite
Abstract
Secondary hyperparathyroidism (SHPT) affects a majority of patients with chronic kidney disease (CKD) in the third and above stages with manifestations of chronic renal failure (CRF), especially in patients undergoing hemodialysis. Despite the temporary effects obtained from taking calcimimetics, there is no significant breakthrough in the treatment of SHPT, and most of the patients require parathyroid surgery (PTS). This review describes the main pathophysiological changes in SHPT, their correction, summarizes the indications for PTS, reflects preoperative preparation, anesthetic management, perioperative intensive care, and possible complications associated with SHPT and CRF. The experience of treating 214 patients with SHPT, 237 PTS (23 in connection with relapse of SHPT), algorithm of examination, preoperative preparation, anesthetic management and perioperative intensive care are presented. In the postoperative period, patients are at risk of severe hypocalcemia and hungry bone syndrome, which require careful monitoring and calcium replenishment.
References
Bureo, J. C, Arévalo, J. C., Antón, J., Adrados, G., Jiménez Morales, J. L., Robles, N. R. (2015). Prevalence of secondary hyperparathyroidism in patients with stage 3 and 4 chronic kidney disease seen in internal medicine. Endocrinol. Nutr., 62, 300–305. https://doi.org/ 10.1016/j.endoen.2015.08.007.
Levin, A., Bakris, G. L, Molitch, M. et al. (2007). Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int., 71, 31–38. https://doi.org/10.1038/sj.ki.5002009.
Ramos, A. M, Albalate, M., Vázquez, S., Caramelo, C., Egido, J., Ortiz, A. (2008). Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients. Kidney Int. Suppl ,74, 111., S88–S93. https://doi.org/10.1038/ki.2008.543.
Cunningham, J., Locatelli, F., Rodriguez, M. (2011). Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin. J. Am. Soc. Nephrol., 6, 913–921. https://doi.org/10.2215/CJN.06040710.
van der Plas, W. Y., Noltes, M. E., van Ginhoven, T. M., Kruijff, S. (2019). Secondary and tertiary hyperparathyroidism: a narrative review. Scand. J. Surg., 109, (4), 271-278. https://doi.org/10.1177/1457496919866015.
Yampolskyi, A. F., Eremeeva, L. F., Shuliak, L. Y. (1999). Kontsentratsyia kortyzola y uroven arteryalnoho davlenyia u bolnykh s termynalnoi pochechnoi nedostatochnostiu na khronycheskom hemodyalyze [Cortisol concentration and blood pressure level in patients with end-stage renal failure on chronic hemodialysis]. Nephrology, 3, 3, 53–56.
Kovalenko, A. E, Lyutkevich, A. V., Tarashchenko, Yu. N. (2016). Hirurgicheskoe lechenie vtorichnogo giperparatireoza pri hronicheskom zabolevanii pochek. Kontsensus evropeyskogo obschestva endokrinnyih hirurgov. [Surgical treatment of secondary hyperparathyroidism in chronic kidney disease. Consensus of the European Society of Endocrine Surgeons]. (6th Workshop of the European Society of Endocrine Surgeons (ESES), May 28th-30st 2015, Varna, Bulgaria). Endocrinology, 21, 339–356. ISSN 1680-1466’ ENDOKRYNOLOGIA’ 2016, VOLUME 21, No. 4.
Block, G. A., Bushinsky, D. A., Cunningham, J. et al. (2017). Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. JAMA, 317, (2), 146–155. https://doi.org/ 10.1001/jama.2016.19456.
Parfrey, P. S., Chertow, G. M., Block, G. A. et al. (2013). The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. J. Clin. Endocrinol. Metab., 98, 4834–4844. https://doi.org/10.1210/jc.2013-2975.
Kim, S. M., Long, J., Montez-Rath, M. E., Leonard, M. B., Norton, J. A., Chertow, G. M. (2016). Rates and outcomes of parathyroidectomy for secondary hyperparathyroidism in the United States. Clin. J. Am. Soc. Nephrol., 11, 1260–1267. https://doi.org/10.2215%2FCJN.10370915.
Ketteler, M., Block, G. A, Evenepoel, P. et al. (2017). Diagnosis, evaluation, prevention, and treatment of chronic kidney diseasemineral and bone disorder: synopsis of the Kidney Disease: Improving Global Outcomes Clinical Practice Guideline Update. Ann. Intern. Med., 2018, 168 (6), 422–430. https://doi.org/ 10.7326/M17-2640.
Gabrielle, K. Steinl and Jennifer H. Kuo. (2021). Surgical Management of Secondary Hyperparathyroidism. Kidney Int. Rep. 2021, Feb, 6, (2), 254–264. https://doi.org/ 10.1016/j.ekir.2020.11.023.
Lau, W. L., Obi, Y., Kalantar-Zadeh, K. (2018). Parathyroidectomy in the management of secondary hyperparathyroidism. Clin. J. Am. Soc. Nephrol., 13, 952–961. https://doi.org/ 10.2215 / CJN.10390917.
Zhang, Y., Lu, Y., Feng, S., Zhan, Z, Shen, H. (2019). Evaluation of laboratory parameters and symptoms after parathyroidectomy in dialysis patients with secondary hyperparathyroidism. Renal Fail., 9, 41, 921–929. https://doi.org/10.1080/ 0886022X.2019.1666724.
National Kidney Foundation. (2003). K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J .Kidney Dis., 42, (suppl 3), S1–S201. PMID: 14520607.
Vincent, M. Brandenburg and Jürgen Floege. (2008). Adynamic bone disease—bone and beyond. NDT Plus, 1 (3). 135–147. https://doi.org/10.1093/ndtplus/sfn040.
Tomiyama, C., Carvalho, A. B., Higa, A., Jorgetti, V., Draibe, S. A., Canziani, M. E. (2010). Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment. J. Bone Miner. Res., 25, 499–504. https://doi.org/10.1359 / jbmr.090735
Udomkarnjananun, S., Kongnatthasate, K., Praditpornsilpa, K., Eiam-Ong, S., Jaber, B. L., Susantitaphong, P. (2019). Treatment of calciphylaxis in CKD: a systematic review and meta-analysis. Kidney Int. Rep., 4, 231–244. https://doi.org/ 10.1016/j.ekir.2018.10.002.
Brandenburg, V. M., Kramann, R., Rothe, H. et al. (2017). Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrol Dial Transplant, 32, 126–132. https://doi.org/10.1093/ndt/gfv438.
Chutia, H., Ruram, A. A., Bhattacharyya, H., Boruah, P., Nath, C. (2013). Association of secondary hyperparathyroidism with hemoglobin level in patients with chronic kidney disease. J. Lab. Physicians, 5,51–54. https://doi.org/10.4103/0974-2727.115935.
Chow, T. L., Chan, T. T., Ho, Y. W., Lam, S. H. (2007), Improvement of anemia after parathyroidectomy in Chinese patients with renal failure undergoing long-term dialysis. Arch. Surg., 142, 644–648. https://doi.org/ 10.1001/archsurg.142.7.644.
Gong, L., Tang, W., Lu, J., Xu, W. (2019). Thermal ablation versus parathyroidectomy for secondary hyperparathyroidism: a metaanalysis. Int. J. Surg., 2019, 70, 13–18. https://doi.org/ 10.1016/j.ijsu.2019.08.004.
Chen, H. H., Lin, C. J., Wu, C. J. et al. (2011). Chemical ablation of recurrent and persistent secondary hyperparathyroidism after subtotal parathyroidectomy. Ann. Surg., 253, 786–790. https://doi.org/10.1097/SLA.0b013e318211ccc2.
Vulpio, C., Bossola, M., Di Stasio, E. et al. (2016). Intra-operative parathyroid hormone monitoring through central laboratory is accurate in renal secondary hyperparathyroidism. Clin. Biochem., 49, 538–543. https://doi.org/10.1016/j.clinbiochem.2016.01.012.
El-Husseini, A., Wang, K., Edon, A. et al. (2018). Value of intraoperative parathyroid hormone assay during parathyroidectomy in dialysis and renal transplant patients with secondary and tertiary hyperparathyroidism. Nephron, 138, 119–128. https://doi.org/doi.org/10.1159/000482016.
Miccoli, P. (2012). Intraoperative parathyroid hormone assay during surgery for secondary hyperparathyroidism: is it time to give up the chase at the hormone? Endocrine, 42, 459–460. https://doi.org/ 10.1007/s12020-012-9724-x.
Hiramitsu, T., Tomosugi, T., Okada, M. et al. (2019). Pre-operative localisation of the parathyroid glands in secondary hyperparathyroidism: a retrospective cohort study. Sci. Rep., 9, 14634. https://doi.org/10.1038/s41598-019-51265-y.
Andrade, J. S., Mangussi-Gomes, J. P., Rocha, L. A. et al. (2014). Localization of ectopic and supernumerary parathyroid glands in patients with secondary and tertiary hyperparathyroidism: surgical description and correlation with preoperative ultrasonography and Tc99m-Sestamibi scintigraphy. Braz. J. Otorhinolaryngol., 80, 29–34. https://doi.org/10.5935/1808-8694.20140008.
Gomes, E. M., Nunes, R. C., Lacativa, P. G. et al. (2007). Ectopic and extranumerary parathyroid glands location in patients with hyperparathyroidism secondary to end stage renal disease. Acta. Cir. Bras., 22, 105–109. https://doi.org/10.1590/s0102-86502007000200005.
Corneci, M., Stanescu, B., Trifanescu, R. et al. (2012). Perioperative management difficulties in parathyroidectomy for primary versus secondary and tertiary hyperparathyroidism. Maedica (Buchar), 7(2), 117–124. PMCID: PMC3557418.
Udelsman, R., Lin, Z., Donovan, P. (2011). The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann. Surg., 253, 585–591. https://doi.org/10.1097/SLA.0b013e318208fed9.
Borysova, V. Y., Dubrov, S. A., Lianskorunskyi, V. N. (2018). Anestezyolohycheskoe obespechenye pry travmatolohycheskoi operatsyy u patsyentky s termynalnoi stadyei khronycheskoi pochechnoi nedostatochnosty nakhodiashcheisia na prohrammnom hemodyalyze. [Anesthetic management during trauma surgery in a patient with end-stage chronic renal failure on programmed hemodialysis]. Pain, anaesthesia and intensive care, 2, 95-104. https://doi.org/10.25284 /2519-2078.2( 83) .2 018.135827.
Suslov, V. V., Hrytsenko S. N. (2012). Osobennosty anestezyy y yntensyvnoi terapyy pry allotransplantatsyy pochky [Features of anesthesia and intensive care for kidney allotransplantation]. Ukrainian Journal of Extreme Medicine named after Kh.O. Mozhaeva, 1, (2), 34–39. http://nbuv.gov.ua/UJRN/Ujem_2012_13_2_7.
Boccardo, P., Remuzzi, G., Galbusera, M. (2004). Platelet dysfunction in renal failure. Semin. Thromb. Hemost, 30, (5), 579 – 589. https://doi.org/10.1055/s-2004-835678.
Jalal, D . I ., Chonchol, M ., Targher, G. (2010). Disorders of hemostasis as sociated with chronic kidney disease. Semin. Thromb. Hemost., 36(1), 34–40. 10.1055/s-0030-1248722. https://doi.org/10.1055/s-0030-1248722.
. Dager, W. E., Kiser, T. H. (2010). Systemic anticoagulation considerations in chronic kidney disease. Adv. Chronic. Kidney Dis, 17, 420–427. https://doi.org/10.1053/j.ackd.2010.06.002.
Folsom, A. R., Lutsey, P. L., Astor, B. C. et al. (2010). Chronic kidney diseas e and venous throm boembolism: a prospective study. Nephrol. Dial. Transplant., 25, 3296–3301. https://doi.org/10.1093/ndt/gfq179.
Wattanakit, K., Cushman, M., Stehman, Breen C. et al. (2008). Chronic kidney disease in creases risk for venous thromboembolism. J. Am. Soc. Nephrol., 1 (19), 135–140. https://doi.org /10.1681/ASN.2007030308.
. Shlipak, M. G., Fried, L. F., Crump, C. et al. (2003). Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation, 107, 87–92. https://doi.org/10.1161 / 01.cir.0000042700.48769.59.
Tay, K. H., Lip, G. Y. (2008). What «drives» the link between the renin-angiotensin- aldosterone system and the prothrombotic state in hypertension? Am. J. Hypertens., 21, 1278–1279. https://doi.org /10.1038/ajh.2008.315.
William, H. Geerts, David, Bergqvist, Graham, F. Pineo, John, A. Heit, Charles, M. Samama, Michael, R. Lassen and Clifford W. Colwell. (2008). Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest., 133, 3815-4535. https://doi.org/10.1378/chest.08-0656.
Giuseppe, Mancia et al. (2013). Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 34 (28), 2159 –2219. https://doi.org/10.1093/eurheartj/eht151.
Morse, S. A., Dang, A., Thakur, V., Shang, R., Reisin, E. (2003). Hypertension in Chronic Dialysis Patients: Pathophysiology, Monitoring, and Treatment. Am. J. Med. Sciences, 325 (4), 194–201. https://doi.org/10.1097/00000441-200304000-00005.
Davina, J. T., Thomas, W. L., Matthew, J. T. et al. (2010). Cardiovascular effects of Angiotensin Converting Enzyme Inhibition or Angiotensin Receptor Blockade in Hemodialysis: A Meta-Analysis. Clin. J. Am. Soc. Nephrol., 5, (4), 623–630. . https://doi.org/10.2215/CJN.07831109.
Doulton,Timothy W. R., MacGregor, Graham A. (2004). Blood pressure in haemodialysis patients: The importance of the relationship between the reninangiotensin-aldosterone system, salt intake and extracellular volume. Jornal of the Renin-Angiotensin-Aldosterone System, 5. (1), 14–22. https://doi.org/ 10.3317/jraas.2004.001.
Bomback, Andrew S., Ksbirsagar, Abbijit V., Ferris, Maria I. et al. (2009). Disordered aldosterone-volume relationship in end-stage kidney disease. Jornal of the Renin-Angiotensin-Aldosterone System, 10 (4), 229–237. https://doi.org/ 10.1177/1470320309352353.
Herzog, C. A., Asinger, R . W., Berger, A. K., et al. (2011). Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes ( KDIGO ). Kidney Int., 80 (6), 572–86. https://doi.org/10.1038/ki.2011.223.
Cai, Q., Mukku, V.K., Ahmad, M. (2013). Coronary artery disease in patients with chronic kidney disease: a clinical update. Curr. Cardiol. Rev., 9 (4), 331–339. https//doi.org/10.2174/1573403X10666140214122234.
Ohtake, T., Kobayashi, S., Moriya, H., et al. (2005). High Prevalence of Occult Coronary Artery Stenosis in Patients with Chronic Kidney Disease at the Initiation of Renal Replacement Therapy: An. Angiographi. Examination. J. Am. Soc. Nephrol., 16, 1141–1148. https//doi.org/10.1681/ASN.2004090765.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.